"SPINRAZA 12 MG/5 ML INTRATECAL INJECTION SOLUTION" TREATMENT WITH NUSINERSEN SODIUM ACTIVE INGREDIENT HAS BEEN LICENSED IN OUR COUNTRY.

 "SPINRAZA 12 mg/5 ml Intrathecal Injectable Solution" treatment with the active ingredient Nusinersen Sodium has been licensed in our country.

Gene Medicineç and Health Products Industry and Trade Inc. 'To date, our Company has procured it from abroad on a prescription basis for personal treatment and made it available to patients, used in the treatment of SMA (Spinal Muscular Atrophy) disease. The license application made by our Company for the drug called "SPINRAZA 12 mg/5 ml Intrathecal Injection Solution" with the active ingredient "Nusinersen Sodium", which is the only treatment method approved by the Ministry of Health (Ministry) and covered by the Social Security Institution (SSI), has been approved. Turkey Pharmaceuticals and the Medical Devices Authority, in its letter dated 29.11.2022 (which we notified on 30.11.2022), stated that the pharmaceutical products on behalf of our Company; He informed us that the license was issued on 25.11.2022 with the number 2022/677.

With the completion of the licensing process, this medicine has been supplied with the alternative reimbursement agreement made between SSI and our company. Sales and marketing rights are given exclusively to our company in Turkey. As of now, the drug in question is the only licensed drug that can be used for the treatment of SMA disease in our country.' He made a statement.